Capital Point Ltd

Capital Point Ltd

TTASE:CPTP
40.90
ILA
-0.60
(-1.45%)
6.77BMarket Cap
Capital Point Ltd
TASE:CPTP
(Tel Aviv Stock Exchange)

Recent

price

40.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
ILS
0.03
0.02
0.01
- -
0.01
0.03
0.02
- -
0.01
0.01
- -
Revenue per Share
-0.05
-0.06
-0.07
-0.05
0.12
0.19
-0.24
0.01
-0.18
0.05
- -
Basic EPS, GAAP
-0.1
-0.05
-0.05
-0.04
-0.04
-0.09
-0.09
-0.05
-0.05
-0.05
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.1
- -
- -
- -
- -
- -
Dividend per Share
- -
1.29
1.22
1.17
1.29
1.3
1.03
1.05
0.88
0.93
0.93
Book Value per Share
- -
1.29
1.22
1.17
1.29
1.3
1.03
1.05
0.88
0.93
0.93
Tangible Book Value per Share
123
123
123
123
123
125
130
134
134
134
134
Basic Weighted Avg Shares
4
3
1
- -
1
4
3
- -
1
2
- -
Sales/Revenue/Turnover
204.99
794.4
1,278.75
114,775
5,046.02
1,024.11
-181.69
8,217.36
1,532.09
795.12
- -
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
1
- -
- -
Depreciation Expense
-6
-7
-8
-6
15
24
-31
2
-24
7
- -
Net Income, GAAP
- -
- -
- -
- -
17.09
22.28
- -
11.99
- -
- -
- -
Effective Tax Rate (%)
-157.22
-267.27
-1,196.74
-52,475
1,967.51
622.4
-1,120.18
707.02
-2,466.77
399.51
- -
Profit Margin (%)
- -
56
60
32
51
3
8
27
46
47
47
Working Capital
- -
3
3
1
- -
- -
3
2
2
2
2
LT Debt
- -
158
150
143
158
165
137
140
117
124
124
Total Equity
- -
- -
- -
- -
18.49
17.09
- -
10.81
- -
9.96
- -
Return on Invested Capital (%)
- -
- -
- -
- -
8.69
13.37
- -
1.06
- -
5.01
- -
Return on Capital (%)
- -
- -
-5.49
-4.3
9.83
14.89
-20.28
1.23
-18.57
6.03
- -
Return on Common Equity (%)

Capital Structure

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
22
23
24
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
134
134
134
Market Capitalization
80
75
68

Working Capital

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
70
74
73
Cash, Cash Equivalents & STI
59
58
64
Accounts Receivable, Net
- -
1
1
Inventories
- -
- -
- -
Total Current Liabilities
25
25
26
Payables & Accruals
- -
- -
- -
ST Debt
22
23
24
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-4.15%
6.19%
Free Cash Flow
- -
15.47%
-6.82%
Net Income, GAAP
- -
-379.67%
-130.45%
Sales/Revenue/Turnover
- -
136.02%
88.03%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
1
2025
- -
- -
2

Semi-annual Earnings Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.01
2024
- -
- -
-0.18
2025
- -
- -
0.05

Semi-annual Dividends Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Business
Capital Point Ltd. (CPTP.TA) is an Israel-based holding company that operates as a venture capital firm specializing in financing and investments in early-stage technology companies, primarily through privatized technological hothouses supporting research and development under Israel's Ministry of Industry and Trades initiatives; its core subsidiaries include MITAG High Tech Ventures Ltd. and Ofakim Hi Tech Ventures Ltd., which manage portfolios encompassing biotechnology, life sciences, medical devices such as dental implants from Dentech Implants Ltd., orthopedic instruments from LRS Ortho Ltd., and energy technologies like gas turbines from Newton Technologies. The company targets peripheral technological entrepreneurship, providing funded opportunities for high-tech projects in sectors including medical devices and biotechnology, with operations centered in Israel and listings on the Tel Aviv Stock Exchange. Founded prior to 2005 with headquarters in Israel, Capital Point maintains a lean structure of approximately four employees while overseeing investments through its hothouse model. No major acquisitions, funding rounds, partnerships, or strategic shifts are reported in the last 1-2 years as of late 2025, with the company sustaining its focus on early-stage high-tech incubation amid stable financials including net sales of around 33.25 million ILS in 2023.